Success Metrics

Clinical Success Rate
20.0%

Based on 1 completed trials

Completion Rate
20%(1/5)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
4(80%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
3
60%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(4)

Detailed Status

Terminated4
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
20.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

completed120%
terminated480%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

NCT04913220
terminatedphase_2

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

NCT05179603
terminatedphase_1

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

NCT04009681
terminatedphase_2

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

NCT04914897
completedphase_2

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

NCT05104567

Clinical Trials (5)

Showing 5 of 5 trials
NCT04913220Phase 1

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Terminated
NCT05179603Phase 2

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Terminated
NCT04009681Phase 1

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

Terminated
NCT04914897Phase 2

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Terminated
NCT05104567Phase 2

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5